Company Profile
BioStem Technologies Stock Price, News & Analysis
- Ticker:
- BSEM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.02 USD (+20.58%)
Close
Last updated: August 6, 2026
—
Market cap
Why the stock is moving
The latest monitored company update is “BioStem Technologies Announces Nasdaq Uplisting.” The corresponding closing-price reaction is not yet available.
Company overview
Perinatal Tissue Regenerative Medicine Company
BioStem Technologies develops, manufactures, and commercializes allograft products derived from perinatal tissue. Its products are used across multiple specialties, particularly surgical care and wound management.
Processing Technology and Product Portfolio
The company uses proprietary BioRetain, CryoTek, and SteriTek processing methods intended to preserve the natural properties of donated tissue. Its brands include Neox, Clarix, VENDAJE, and American Amnion.
Hospital Commercialization Transition
Following the acquisition of BioTissue surgical and wound-care assets, BioStem is building a broader hospital-focused commercial organization, expanding its direct sales team and group purchasing organization coverage. The release did not identify a specific asset-level clinical or regulatory catalyst.
Future catalysts
BioStem Technologies’ catalysts are wound-care product adoption and any commercial update that shows the regenerative-medicine platform is scaling. The market will care about recurring demand.
Recent news
- 01
BioStem Technologies Announces Nasdaq Uplisting
Source: BioStem Technologies
- 02
BioStem Technologies to Host Second Quarter 2026 Financial Results Conference Call on August 12, 2026
Source: BioStem Technologies
- 03
BioStem Technologies Publicly Files Form 10 Registration Statement with the Securities and Exchange Commission
Source: BioStem Technologies
- 04
BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference
Source: BioStem Technologies
- 05
BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
Source: BioStem Technologies
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BioStem Technologies (BSEM)?
BioStem Technologies (BSEM) most recently closed at 4.02 USD, a +20.58% move versus the previous session.
What does BioStem Technologies do?
Perinatal Tissue Regenerative Medicine Company BioStem Technologies develops, manufactures, and commercializes allograft products derived from perinatal tissue. Its products are used across multiple specialties, particularly surgical care and wound management. Processing Technology and Product Portfolio The company uses proprietary BioRetain, CryoTek, and...
On which exchange is BSEM stock listed?
BioStem Technologies (BSEM) is associated with NASDAQ, United States, Biopharma.
What is Perinatal?
Perinatal Tissue Regenerative Medicine Company BioStem Technologies develops, manufactures, and commercializes allograft products derived from perinatal tissue.
Which conditions is BioStem Technologies targeting with Perinatal?
Perinatal Tissue Regenerative Medicine Company BioStem Technologies develops, manufactures, and commercializes allograft products derived from perinatal tissue. Its products are used across multiple specialties, particularly surgical care and wound management. Processing Technology and Product Portfolio The company uses proprietary BioRetain, CryoTek, and...
How does BioStem Technologies describe recent progress with Perinatal?
BioStem Technologies’ catalysts are wound-care product adoption and any commercial update that shows the regenerative-medicine platform is scaling. The market will care about recurring demand.
What is Tissue?
Perinatal Tissue Regenerative Medicine Company BioStem Technologies develops, manufactures, and commercializes allograft products derived from perinatal tissue.
What should investors watch for with Tissue?
BioStem Technologies’ catalysts are wound-care product adoption and any commercial update that shows the regenerative-medicine platform is scaling. The market will care about recurring demand.